Topiramate and cognitive impairment: Evidence and clinical implications

Therapeutic Advances in Drug Safety

Volumn 3, Issue 6, 2012, Pages 279-289

  Mula, Marco ^a  

^a University Hospital Maggiore della Carita   (Italy)

Author keywords

adverse event; antiepileptic drugs; cognition; epilepsy; headache; neuropsychology; topiramate

Indexed keywords

AMITRIPTYLINE; CARBAMAZEPINE; ETIRACETAM; LAMOTRIGINE; TOPIRAMATE;

BRAIN DISEASE; COGNITION; COGNITIVE DEFECT; CONCENTRATION LOSS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; ESSENTIAL TREMOR; FOCAL EPILEPSY; HEADACHE; HUMAN; MEMORY DISORDER; MIGRAINE; MONOTHERAPY; NEUROLOGIC DISEASE; NEUROPSYCHOLOGY; PARESTHESIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; ROLANDIC EPILEPSY;

EID: 84875521259     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098612455357     Document Type: Review

References (100)

1. Adelman J. Freitag F. Lainez M. Shi Y. Ascher S. Mao L. (2008) Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials. Pain Med 9: 175–185.
2. Aldenkamp A. (2000) Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 54: 271–272.
3. Aldenkamp A. Baker G. Mulder O. Chadwick D. Cooper P. Doelman J. (2000) A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 41: 1167–1178.
4. Aldenkamp A. De Krom M. Reijs R. (2003) Newer antiepileptic drugs and cognitive issues. Epilepsia 44(Suppl. 4): 21–29.
5. Arif H. Buchsbaum R. Pierro J. Whalen M. Sims J. Resor S. Jr. (2010) Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy. Arch Neurol 67: 408–415.
6. Arroyo S. Dodson W. Privitera M. Glauser T. Naritoku D. Dlugos D. (2005) Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol Scand 112: 214–222.
7. Backonja M. (2002) Use of anticonvulsants for treatment of neuropathic pain. Neurology 59: S14–S17.
8. Baker G. Taylor J. Aldenkamp A. (2011) Newly diagnosed epilepsy: cognitive outcome after 12 months. Epilepsia 52: 1084–1091.
9. Ben-Menachem E. Henriksen O. Dam M. Mikkelsen M. Schmidt D. Reid S. (1996) Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 37: 539–543.
10. Biton V. Montouris G. Ritter F. Riviello J. Reife R. Lim P. (1999) A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 52: 1330–1337.
11. Blum D. Meador K. Biton V. Fakhoury T. Shneker B. Chung S. (2006) Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology 67: 400–406.
12. Brandl U. Kurlemann G. Neubauer B. Rettig K. Schauble B. Schreiner A. (2010) Seizure and cognitive outcomes in children and adolescents with epilepsy treated with topiramate. Neuropediatrics 41: 113–120.
13. Burton L. Harden C. (1997) Effect of topiramate on attention. Epilepsy Res 27: 29–32.
14. Cappa S. Ortelli P. Garibotto V. Zamboni M. (2007) Reversible nonfluent aphasia and left frontal hypoperfusion during topiramate treatment. Epilepsy Behav 10: 192–194.
15. Connor G. Edwards K. Tarsy D. (2008) Topiramate in essential tremor: findings from double-blind, placebo-controlled, crossover trials. Clin Neuropharmacol 31: 97–103.
16. Coppola G. Verrotti A. Resicato G. Ferrarelli S. Auricchio G. Operto F. (2008) Topiramate in children and adolescents with epilepsy and mental retardation: a prospective study on behavior and cognitive effects. Epilepsy Behav 12: 253–256.
17. De Ciantis A. Muti M. Piccolini C. Principi M. Di Renzo A. De Ciantis R. (2008) A functional MRI study of language disturbances in subjects with migraine headache during treatment with topiramate. Neurol Sci 29(Suppl. 1): S141–S143.
18. Delorenzo R. Sombati S. Coulter D. (2000) Effects of topiramate on sustained repetitive firing and spontaneous recurrent seizure discharges in cultured hippocampal neurons. Epilepsia 41(Suppl. 1): S40–S44.
19. Diamond M. Dahlof C. Papadopoulos G. Neto W. Wu S. (2005) Topiramate improves health-related quality of life when used to prevent migraine. Headache 45: 1023–1030.
20. Diener H. Bussone G. Van Oene J. Lahaye M. Schwalen S. Goadsby P. (2007) Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 27: 814–823.
21. Dodick D. Silberstein S. Saper J. Freitag F. Cady R. Rapoport A. (2007) The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache 47: 1398–1408.
22. Dodrill C. (1975) Effects of sulthiame upon intellectual, neuropsychological, and social functioning abilities among adult epileptics: comparison with diphenylhydantoin. Epilepsia 16: 617–625.
23. Ferraro D. Di Trapani G. (2008) Topiramate in the prevention of pediatric migraine: literature review. J Headache Pain 9: 147–150.
24. Froscher W. Schier K. Hoffmann M. Meyer A. May T. Rambeck B. (2005) Topiramate: a prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy. Epileptic Disord 7: 237–248.
25. Gibbs J. Sombati S. Delorenzo R. Coulter D. (2000) Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 41(Suppl. 1): S10–S16.
26. Glauser T. Dlugos D. Dodson W. Grinspan A. Wang S. Wu S. (2007) Topiramate monotherapy in newly diagnosed epilepsy in children and adolescents. J Child Neurol 22: 693–699.
27. Gomer B. Wagner K. Frings L. Saar J. Carius A. Harle M. (2007) The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate. Epilepsy Behav 10: 486–494.
28. Groselj J. Guerrini R. Van Oene J. Lahaye M. Schreiner A. Schwalen S. (2005) Experience with topiramate monotherapy in elderly patients with recent-onset epilepsy. Acta Neurol Scand 112: 144–150.
29. Gross-Tsur V. Shalev R. (2004) Reversible language regression as an adverse effect of topiramate treatment in children. Neurology 62: 299–300.
30. Hill M. Gordon C. Situnayake R. Heath D. (1994) Sulfasalazine induced seizures and dysphasia. J Rheumatol 21: 748–749.
31. Huang C. Pai M. Tsai J. (2008) Comparative cognitive effects of levetiracetam and topiramate in intractable epilepsy. Psychiatry Clin Neurosci 62: 548–553.
32. Jansen J. Aldenkamp A. Marian Majoie H. Reijs R. De Krom M. Hofman P. (2006) Functional MRI reveals declined prefrontal cortex activation in patients with epilepsy on topiramate therapy. Epilepsy Behav 9: 181–185.
33. Jette N. Hemming K. Hutton J. Marson A. (2008) Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev: CD001417.
34. Johannessen Landmark C. (2008) Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 22: 27–47.
35. Kang H. Eun B. Wu Lee C. Ku Moon H. Kim J. Wook Kim D. (2007) The effects on cognitive function and behavioral problems of topiramate compared to carbamazepine as monotherapy for children with benign Rolandic epilepsy. Epilepsia 48: 1716–1723.
36. Kanner A. Wuu J. Faught E. Tatum W. Fix A. French J. (2003) A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav 4: 548–552.
37. Kennedy G. Lhatoo S. (2008) CNS adverse events associated with antiepileptic drugs. CNS Drugs 22: 739–760.
38. Keskinbora K. Aydinli I. (2008) A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clin Neurol Neurosurg 110: 979–984.
39. Kluger G. Schauble B. Rettig K. Schreiner A. Holthausen H. (2009) Effectiveness of low dose of topiramate following rapid titration in multiply handicapped children and difficult-to-treat epilepsy. Neuropediatrics 40: 61–65.
40. Kockelmann E. Elger C. Helmstaedter C. (2003) Significant improvement in frontal lobe associated neuropsychological functions after withdrawal of topiramate in epilepsy patients. Epilepsy Res 54: 171–178.
41. Krakow K. Lengler U. Rettig K. Schreiner A. Schauble B. (2007) Topiramate in add-on therapy: results from an open-label, observational study. Seizure 16: 593–600.
42. Kuzniecky R. Hetherington H. Ho S. Pan J. Martin R. Gilliam F. (1998) Topiramate increases cerebral GABA in healthy humans. Neurology 51: 627–629.
43. Kuzniecky R. Ho S. Pan J. Martin R. Gilliam F. Faught E. (2002) Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology 58: 368–372.
44. Lee H. Jung D. Suh C. Kwon S. Park S. (2006) Cognitive effects of low-dose topiramate monotherapy in epilepsy patients: a 1-year follow-up. Epilepsy Behav 8: 736–741.
45. Leniger T. Thone J. Wiemann M. (2004) Topiramate modulates Ph of hippocampal Ca3 neurons by combined effects on carbonic anhydrase and Cl–/HCO3– exchange. Br J Pharmacol 142: 831–842.
46. Lewis D. Winner P. Saper J. Ness S. Polverejan E. Wang S. (2009) Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age. Pediatrics 123: 924–934.
47. Lhatoo S. Sander J. Wong I. (2000) Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 54: 270–271; author reply 271-272.
48. Lipton R. Silberstein S. Dodick D. Cady R. Freitag F. Mathew N. (2011) Topiramate intervention to prevent transformation of episodic migraine: the Topiramate Intrepid Study. Cephalalgia 31: 18–30.
49. Loring D. Williamson D. Meador K. Wiegand F. Hulihan J. (2011) Topiramate dose effects on cognition: a randomized double-blind study. Neurology 76: 131–137.
50. Luykx J. Mason M. Ferrari M. Carpay J. (2009) Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine. Clin Pharmacol Ther 85: 283–288.
51. Magis D. Schoenen J. (2011) Treatment of migraine: update on new therapies. Curr Opin Neurol 24: 203–210.
52. Malessa R. Gendolla A. Steinberg B. Schmitt L. Bornhoevd K. Djelani M. (2010) Prevention of episodic migraine with topiramate: a prospective 24-week, open-label, flexible-dose clinical trial with optional 24 weeks follow-up in a community setting. Curr Med Res Opin 26: 1119–1129.
53. Marino S. Meador K. Loring D. Okun M. Fernandez H. Fessler A. (2009) Subjective perception of cognition is related to mood and not performance. Epilepsy Behav 14: 459–464.
54. Marson A. Al-Kharusi A. Alwaidh M. Appleton R. Baker G. Chadwick D. (2007a) The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 369: 1000–1015.
55. Marson A. Al-Kharusi A. Alwaidh M. Appleton R. Baker G. Chadwick D. (2007b) The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 369: 1016–1026.
56. Martin R. Kuzniecky R. Ho S. Hetherington H. Pan J. Sinclair K. (1999) Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 52: 321–327.
57. McLean M. Bukhari A. Wamil A. (2000) Effects of topiramate on sodium-dependent action-potential firing by mouse spinal cord neurons in cell culture. Epilepsia 41(Suppl. 1): S21–S24.
58. Meador K. Loring D. Hulihan J. Kamin M. Karim R. (2003) Differential cognitive and behavioral effects of topiramate and valproate. Neurology 60: 1483–1488.
59. Meador K. Loring D. Vahle V. Ray P. Werz M. Fessler A. (2005) Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology 64: 2108–2114.
60. Mecarelli O. Piacenti A. Pulitano P. Vicenzini E. Rizzo C. Rinalduzzi S. (2001) Clinical and electroencephalographic effects of topiramate in patients with epilepsy and healthy volunteers. Clin Neuropharmacol 24: 284–289.
61. Muehlbacher M. Nickel M. Kettler C. Tritt K. Lahmann C. Leiberich P. (2006) Topiramate in treatment of patients with chronic low back pain: a randomized, double-blind, placebo-controlled study. Clin J Pain 22: 526–531.
62. Mula M. Hesdorffer D. Trimble M. Sander J. (2009) The role of titration schedule of topiramate for the development of depression in patients with epilepsy. Epilepsia 50: 1072–1076.
63. Mula M. Pini S. Cassano G. (2007) The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 27: 263–272.
64. Mula M. Sander J. Trimble M. (2006) The role of hippocampal sclerosis in antiepileptic drug-related depression in patients with epilepsy: a study on levetiracetam. Seizure 15: 405–408.
65. Mula M. Trimble M. (2006) Neuropharmacological aspects of cognitive neurorehabilitation in epilepsy. Behav Neurol 17: 69–75.
66. Mula M. Trimble M. (2009) Antiepileptic drug-induced cognitive adverse effects: potential mechanisms and contributing factors. CNS Drugs 23: 121–137.
67. Mula M. Trimble M. Lhatoo S. Sander J. (2003a) Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 44: 659–663.
68. Mula M. Trimble M. Thompson P. Sander J. (2003b) Topiramate and word-finding difficulties in patients with epilepsy. Neurology 60: 1104–1107.
69. Nelles G. Delbruck A. Schulze L. Kademann B. Bornhoevd K. Schafer S. (2009) Topiramate for migraine prevention in a naturalistic setting: results from an open label, flexible dose study. Headache 49: 1454–1465.
70. Nelles G. Schmitt L. Humbert T. Becker V. Sandow P. Bornhoevd K. (2010) Prevention of episodic migraines with topiramate: results from a non-interventional study in a general practice setting. J Headache Pain 11: 33–44.
71. Novotny E. Renfroe B. Yardi N. Nordli D. Ness S. Wang S. (2010) Randomized trial of adjunctive topiramate therapy in infants with refractory partial seizures. Neurology 74: 714–720.
72. Ojemann L. Ojemann G. Dodrill C. Crawford C. Holmes M. Dudley D. (2001) Language disturbances as side effects of topiramate and zonisamide therapy. Epilepsy Behav 2: 579–584.
73. Ondo W. Jankovic J. Connor G. Pahwa R. Elble R. Stacy M. (2006) Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology 66: 672–677.
74. Pandina G. Ness S. Polverejan E. Yuen E. Eerdekens M. Bilder R. (2010) Cognitive effects of topiramate in migraine patients aged 12 through 17 years. Pediatr Neurol 42: 187–195.
75. Pina-Garza J. Schwarzman L. Wiegand F. Hulihan J. (2011) A pilot study of topiramate in childhood absence epilepsy. Acta Neurol Scand 123: 54–59.
76. Privitera M. Fincham R. Penry J. Reife R. Kramer L. Pledger G. (1996) Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-800-and 1,000-mg daily dosages. Topiramate YE Study Group. Neurology 46: 1678–1683.
77. Ramsay E. Faught E. Krumholz A. Naritoku D. Privitera M. Schwarzman L. (2010) Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized double-blind clinical trial. Epilepsia 51: 1970–1977.
78. Ramsay R. Uthman B. Pryor F. Rowan A. Bainbridge J. Spitz M. (2008) Topiramate in older patients with partial-onset seizures: a pilot double-blind, dose-comparison study. Epilepsia 49: 1180–1185.
79. Rizzato B. Leone G. Misaggi G. Zivi I. Diomedi M. (2011) Efficacy and tolerability of pregabalin versus topiramate in the prophylaxis of chronic daily headache with analgesic overuse: an open-label prospective study. Clin Neuropharmacol 34: 74–78.
80. Rowan A. Ramsay R. Collins J. Pryor F. Boardman K. Uthman B. (2005) New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 64: 1868–1873.
81. Sachdeo R. Glauser T. Ritter F. Reife R. Lim P. Pledger G. (1999) A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate Yl Study Group. Neurology 52: 1882–1887.
82. Salinsky M. Storzbach D. Oken B. Spencer D. (2007) Topiramate effects on the EEG and alertness in healthy volunteers: a different profile of antiepileptic drug neurotoxicity. Epilepsy Behav 10: 463–469.
83. Shank R. Gardocki J. Streeter A. Maryanoff B. (2000) An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 41(Suppl. 1): S3–S9.
84. Shank R. Gardocki J. Vaught J. Davis C. Schupsky J. Raffa R. (1994) Topiramate: preclinical evaluation of structurally novel anticonvulsant. Epilepsia 35: 450–460.
85. Silberstein S. Lipton R. Dodick D. Freitag F. Mathew N. Brandes J. (2009) Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache 49: 1153–1162.
86. Silberstein S. Lipton R. Dodick D. Freitag F. Ramadan N. Mathew N. (2007) Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 47: 170–180.
87. Smith M. Gevins A. McEvoy L. Meador K. Ray P. Gilliam F. (2006) Distinct cognitive neurophysiologic profiles for lamotrigine and topiramate. Epilepsia 47: 695–703.
88. Spina E. Perugi G. (2004) Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 6: 57–75.
89. Stefan H. Hubbertz L. Peglau I. Berrouschot J. Kasper B. Schreiner A. (2008) Epilepsy outcomes in elderly treated with topiramate. Acta Neurol Scand 118: 164–174.
90. Stewart S. (2005) The effects of benzodiazepines on cognition. J Clin Psychiatry 66(Suppl. 2): 9–13.
91. Thompson P. Baxendale S. Duncan J. Sander J. (2000) Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 69: 636–641.
92. Tremont-Lukats I. Megeff C. Backonja M. (2000) Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy. Drugs 60: 1029–1052.
93. Wang W. Li J. Wu X. (2003) Quantitative EEG effects of topiramate. Clin Electroencephalogr 34: 87–92.
94. Werz M. Schoenberg M. Meador K. Loring D. Ray P. Kaul-Gupta R. (2006) Subjective preference for lamotrigine or topiramate in healthy volunteers: relationship to cognitive and behavioral functioning. Epilepsy Behav 8: 181–191.
95. White H. (2003) Mechanism of action of newer anticonvulsants. J Clin Psychiatry 64(Suppl. 8): 5–8.
96. White H. Brown S. Woodhead J. Skeen G. Wolf H. (1997) Topiramate enhances gaba-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 28: 167–179.
97. Wilensky A. Friel P. Ojemann L. Dodrill C. McCormick K. Levy R. (1985) Zonisamide in epilepsy: a pilot study. Epilepsia 26: 212–220.
98. Winner P. Pearlman E. Linder S. Jordan D. Fisher A. Hulihan J. (2005) Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial. Headache 45: 1304–1312.
99. Zhang L. Huang J. Zhuang J. Huang L. Zhao Z. (2011) Topiramate as an adjunctive treatment for refractory partial epilepsy in the elderly. J Int Med Res 39: 408–415.
100. Zhang X. Velumian A. Jones O. Carlen P. (2000) Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 41(Suppl. 1): S52–S60.